Tadalafil Prevents Acute Heart Failure with Reduced Ejection Fraction in Mice
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tadalafil Prevents Acute Heart Failure with Reduced Ejection Fraction in Mice
Authors
Keywords
Infarct size, Apoptosis, LV function, Cardiomyopathy, Phosphodiesterase-5 inhibitors
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 28, Issue 6, Pages 493-500
Publisher
Springer Nature
Online
2014-10-16
DOI
10.1007/s10557-014-6559-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Induction of MicroRNA-21 With Exogenous Hydrogen Sulfide Attenuates Myocardial Ischemic and Inflammatory Injury in Mice
- (2014) S. Toldo et al. Circulation-Cardiovascular Genetics
- TGF- mediates early angiogenesis and latent fibrosis in an Emilin1-deficient mouse model of aortic valve disease
- (2014) C. Munjal et al. Disease Models & Mechanisms
- Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension
- (2013) Rodrigo C. Santos et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice
- (2013) Saisudha Koka et al. FREE RADICAL BIOLOGY AND MEDICINE
- Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction
- (2013) Margaret M. Redfield et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo
- (2012) Dirk Westermann et al. BASIC RESEARCH IN CARDIOLOGY
- Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy
- (2012) Elisa Giannetta et al. CIRCULATION
- PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) Trial
- (2012) Margaret M. Redfield et al. Circulation-Heart Failure
- Tadalafil for the treatment of pulmonary arterial hypertension
- (2012) Maria Klara Frey et al. EXPERT OPINION ON PHARMACOTHERAPY
- Tadalafil for the Treatment of Pulmonary Arterial Hypertension
- (2012) Ronald J. Oudiz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection
- (2012) Rakesh C. Kukreja et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-Inflammatory and Cardioprotective Effects of Tadalafil in Diabetic Mice
- (2012) Amit Varma et al. PLoS One
- Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway
- (2011) Vinh Q. Chau et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure
- (2010) Marco Guazzi et al. Circulation-Heart Failure
- Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice
- (2009) Peter Pokreisz et al. CIRCULATION
- Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G-Dependent Generation of Hydrogen Sulfide
- (2009) F. N. Salloum et al. CIRCULATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now